Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25350548 | 0.72 | PKM (0.68) | PKMPOLBCYP1A2ALDH1A1MAPT | |
| SCHEMBL10846547 | 0.70 | PKM (0.66) | PKMPOLBCYP1A2ALDH1A1MAPT | |
| SCHEMBL5674937 | 0.70 | POLB (0.37) | POLBALDH1A1KMT2A | |
| SCHEMBL12158282 | 0.68 | PKM (0.62) | PKMPOLBCYP1A2ALDH1A1TSHR | |
| SCHEMBL5673306 | 0.65 | MAPT (0.55) | ALDH1A1TSHRMAPTGPR84KMT2A | |
| SCHEMBL6024344 | 0.65 | POLB (1.00) | PKMPOLBALDH1A1TSHRMAPT | |
| SCHEMBL2575841 | 0.64 | DRD4 (0.52) | ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL803563 | 0.63 | PKM (0.54) | PKMPOLBCYP1A2ALDH1A1TSHR | |
| SCHEMBL2588526 | 0.62 | DRD4 (0.53) | ALDH1A1NPSR1KMT2A | |
| SCHEMBL5552693 | 0.62 | SCN9A (0.55) | PKMPOLBALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037916-B2 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2004062609-A2 | PYRIMIDINE DERIVATIVES AS IL-8 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA, LLC | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | CXCL8, IL1RN, IL18 | PKM 3575/4885POLB 610/4885CYP1A2 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.